Form D · Biotechnology

Sarepta Therapeutics, Inc.

Cambridge, MA · CIK 0000873303

Offering snapshot reported Feb 28, 2020 · SEC filing

Reported sold
$400M
Offering amount: $400M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 14, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 28, 2020Initial$399,999,980No comparison1SEC filing
Nov 25, 2019Initial$30,499,980No comparison1SEC filing
Apr 2, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-361658
SHARES ISSUED PURSUANT TO THE STOCK PURCHASE AGREEMENT, DATED DECEMBER 21, 2019, BETWEEN SAREPTA THERAPEUTICS, INC. AND ROCHE FINANCE LTD.

Source: Form D, filed Feb 28, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Richard J. Barry Director
M. Kathleen Behrens Director
Michael W. Bonney Director
William Ciambrone Executive
Alexander Cumbo Executive
Mary Ann Gray Director
David Tyronne Howton Executive
Douglas S. Ingram Director, Executive
Sandesh Mahatme Executive
John C. Martin Director
Claude Nicaise Director
Gilmore O'neill Executive
Hans Wigzell Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
215 First Street Suite 415
Cambridge, MA, 02142